1,3,5-triaza-7-phosphaadamantane has been researched along with ruthenium in 11 studies
| Studies (1,3,5-triaza-7-phosphaadamantane) | Trials (1,3,5-triaza-7-phosphaadamantane) | Recent Studies (post-2010) (1,3,5-triaza-7-phosphaadamantane) | Studies (ruthenium) | Trials (ruthenium) | Recent Studies (post-2010) (ruthenium) |
|---|---|---|---|---|---|
| 44 | 0 | 33 | 6,854 | 7 | 3,883 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bergamo, A; Brescacin, L; Cocchietto, M; Delfino, R; Dyson, PJ; Geldbach, TJ; Laurenczy, G; Sava, G; Scolaro, C | 1 |
| Gossens, C; Rothlisberger, U; Tavernelli, I | 1 |
| Eads, K; Enow, RA; Frost, BJ; Krogstad, DA; Lee, WC; Sears, JM | 1 |
| Bergamini, P; Ferretti, V; Fogagnolo, M; Marchi, A; Marvelli, L; Sforza, F | 1 |
| Plavec, J; Seršen, S; Šket, P; Turel, I | 1 |
| Alessio, E; Arcangeli, A; Balducci, G; Battistin, F; Messori, L; Pillozzi, S; Scaletti, F | 1 |
| Badillo Patzmay, GV; Kwiecień, A; Lupidi, G; Nabissi, M; Pettinari, C; Pettinari, R; Santoni, G; Smoleński, P; Wołoszyn, A | 1 |
| Nordlander, E; Quintero, MAS; Smith, GS; Stringer, T; Wiesner, L | 1 |
| Fadare, OA; Olasunkanmi, LO; Tabrizi, L | 1 |
| Burmeister, H; Kladnik, J; Kljun, J; Ott, I; Romero-Canelón, I; Turel, I | 1 |
| Bermejo-Casadesús, C; Del Pino, JMV; García-Maroto, F; Massaguer, A; Romerosa, A; Scalambra, F | 1 |
11 other study(ies) available for 1,3,5-triaza-7-phosphaadamantane and ruthenium
| Article | Year |
|---|---|
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Topics: Adamantane; Animals; Antineoplastic Agents; Benzene Derivatives; Buffers; Cell Line, Tumor; DNA; Female; Humans; Hydrolysis; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred CBA; Organometallic Compounds; Organophosphorus Compounds; Ruthenium; Sodium Chloride; Solutions; Structure-Activity Relationship; Tissue Distribution; Xenograft Model Antitumor Assays | 2005 |
DNA structural distortions induced by ruthenium-arene anticancer compounds.
Topics: Adamantane; Antineoplastic Agents; Binding Sites; Calixarenes; Computer Simulation; DNA; Ethylenediamines; Guanine; Models, Chemical; Models, Molecular; Molecular Conformation; Organometallic Compounds; Organophosphorus Compounds; Ruthenium; Stereoisomerism; Water | 2008 |
Hemilabile β-aminophosphine ligands derived from 1,3,5-triaza-7-phosphaadamantane: application in aqueous ruthenium catalyzed nitrile hydration.
Topics: Adamantane; Catalysis; Ligands; Models, Molecular; Molecular Structure; Nitriles; Organometallic Compounds; Organophosphorus Compounds; Phosphines; Ruthenium; Water | 2013 |
Acetylcholine-like and trimethylglycine-like PTA (1,3,5-triaza-7-phosphaadamantane) derivatives for the development of innovative Ru- and Pt-based therapeutic agents.
Topics: Adamantane; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; K562 Cells; Models, Molecular; Molecular Structure; Organometallic Compounds; Organophosphorus Compounds; Platinum; Ruthenium; Structure-Activity Relationship | 2014 |
Interactions of two cytotoxic organoruthenium(II) complexes with G-quadruplex.
Topics: Adamantane; Antineoplastic Agents; Binding Sites; Coordination Complexes; Crystallography, X-Ray; Cymenes; Deuterium; G-Quadruplexes; Magnetic Resonance Spectroscopy; Molecular Conformation; Monoterpenes; Nucleic Acid Denaturation; Organometallic Compounds; Organophosphorus Compounds; Ruthenium; Ultraviolet Rays | 2016 |
Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
Topics: Adamantane; Antineoplastic Agents; Bromides; Cell Line, Tumor; Cell Survival; Chlorides; Coordination Complexes; Cytochromes c; Filaggrin Proteins; HCT116 Cells; Humans; Hydrogen-Ion Concentration; Imidazoles; Indazoles; Inhibitory Concentration 50; Ligands; Oligonucleotides; Organometallic Compounds; Organophosphorus Compounds; Protons; Ribonuclease, Pancreatic; Ruthenium; Solubility; Structure-Activity Relationship; Water | 2016 |
Ru(ii)-(PTA) and -mPTA complexes with N
Topics: 2,2'-Dipyridyl; Adamantane; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coordination Complexes; Crystallography, X-Ray; Humans; Multiple Myeloma; Nitrogen; Organophosphorus Compounds; Phenanthrolines; Ruthenium | 2017 |
Evaluation of PTA-derived ruthenium(II) and iridium(III) quinoline complexes against chloroquine-sensitive and resistant strains of the Plasmodium falciparum malaria parasite.
Topics: Adamantane; Animals; Antimalarials; Chloroquine; Coordination Complexes; Drug Resistance; Iridium; Organophosphorus Compounds; Plasmodium falciparum; Quinolines; Ruthenium | 2019 |
Experimental and theoretical investigations of cyclometalated ruthenium(ii) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities in various can
Topics: Adamantane; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coordination Complexes; Cyclooxygenase Inhibitors; Drug Stability; HEK293 Cells; Humans; Ibuprofen; Ligands; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Naproxen; Organophosphorus Compounds; Reactive Oxygen Species; Ruthenium | 2019 |
Towards Identification of Essential Structural Elements of Organoruthenium(II)-Pyrithionato Complexes for Anticancer Activity.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Coordination Complexes; Drug Screening Assays, Antitumor; Humans; Organophosphorus Compounds; Pyridines; Ruthenium; Thiones; Wound Healing | 2019 |
Study of the biological activity of photoactive bipyridyl-Ru(II) complexes containing 1,3,5-triaza-7-phosphaadamantane (PTA).
Topics: 2,2'-Dipyridyl; Antineoplastic Agents; Coordination Complexes; DNA; Humans; Organophosphorus Compounds; Ruthenium | 2023 |